Jeil Pharma Holdings Inc (KRX:002620)
South Korea
· Delayed Price · Currency is KRW 8,520.00
-270.00 (-3.07%)
At close: Mar 9, 2026
Jeil Pharma Holdings Revenue
Jeil Pharma Holdings had revenue of 161.36B KRW in the quarter ending September 30, 2025, a decrease of -15.07%. This brings the company's revenue in the last twelve months to 707.15B, down -9.20% year-over-year. In the year 2024, Jeil Pharma Holdings had annual revenue of 779.82B, down -3.01%.
Revenue (ttm)
707.15B
Revenue Growth
-9.20%
P/S Ratio
0.18
Revenue / Employee
19.11B
Employees
37
Market Cap
130.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 779.82B | -24.22B | -3.01% |
| Dec 31, 2023 | 804.04B | 11.08B | 1.40% |
| Dec 31, 2022 | 792.96B | 30.40B | 3.99% |
| Dec 31, 2021 | 762.57B | 571.30M | 0.07% |
| Dec 31, 2020 | 762.00B | 30.19B | 4.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kyongbo Pharmaceutical | 252.20B |
| HANDOK | 516.37B |
| Ildong Holdings | 620.44B |
| Whan In Pharm | 256.32B |
| Ilsung Is | 66.51B |
| CKD Bio | 159.93B |
| Dongwha Pharm.Co.,Ltd | 493.33B |
| Daihan Pharmaceutical | 209.00B |